Sentence examples for development of arteriosclerosis from inspiring English sources

Plasma biomarkers such as glucose, lipids, Homocysteine (Hcy), N-terminal pro-brain natriuretic peptide (NT-proBNP) have been shown to be involved the development of arteriosclerosis.

Accumulating evidence indicates the involvement of vascular progenitor cells in the development of arteriosclerosis, including transplant arteriosclerosis, angioplasty-induced restenosis, vein graft atherosclerosis, and spontaneous atherosclerosis.

CRP2 plays a critical role in attenuating the development of arteriosclerosis [ 3, 4].

This oxidative stress might explain the further development of arteriosclerosis, hypercholesterolemia, and diabetes mellitus in people exposed to organophosphate compounds.

An increase in carotid artery intima-media thickness (IMT) is an early phenomenon in the development of arteriosclerosis.

Taken together, these data underscore the hypothesis that C-peptide could play a direct role in the development of arteriosclerosis.

Conditions that prevent or precipitate the development of symptomatic arteriosclerosis evolve with time and may also be different in various regions of the world [4], [9].

A short course of low-dose anti-CD3 monotherapy could not completely prevent the development of transplant arteriosclerosis in vascularized heart or aorta allografts (data not shown) using the protocol developed for this study.

Long-term air pollution exposure has been associated with stroke hospitalisations and mortality, 58 and there is growing evidence that it has an impact on the development of carotid arteriosclerosis which is a precursor of stroke.

In such patients, hypertension and dyslipidemia may be involved in the development of intrarenal arteriosclerosis or glomerular ischemia to reduce GFR and albuminuria (34, 35), but concomitant PTC hypoxia may cause increased urinary megalin excretion.

We have shown that ex vivo expanded human CD4+FOXP3+ T cells can prevent the development of transplant arteriosclerosis (TA) in transplanted human vessel allografts and the rejection of human skin allografts (9, 10).